Zynex (NASDAQ:ZYXI) Releases Q4 2024 Earnings Guidance

Zynex (NASDAQ:ZYXI) updated its fourth quarter 2024 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of 0.090- for the period, compared to the consensus estimate of 0.100. The company issued revenue guidance of $53.6 million-, compared to the consensus revenue estimate of $53.3 million. Zynex also updated its FY 2024 guidance to 0.200- EPS.

Analyst Ratings Changes

Several equities analysts have commented on the stock. HC Wainwright restated a “buy” rating and issued a $16.00 price target on shares of Zynex in a research note on Wednesday, September 4th. Royal Bank of Canada dropped their price target on shares of Zynex from $12.00 to $11.00 and set an “outperform” rating for the company in a research note on Tuesday, October 8th.

Zynex Stock Up 2.8 %

Shares of Zynex stock traded up $0.23 during trading on Thursday, hitting $8.59. 151,003 shares of the stock were exchanged, compared to its average volume of 173,447. The stock has a market cap of $272.65 million, a price-to-earnings ratio of 47.72 and a beta of 0.54. The firm’s 50-day moving average price is $7.96 and its 200 day moving average price is $9.23. Zynex has a 12-month low of $7.04 and a 12-month high of $13.77. The company has a debt-to-equity ratio of 1.79, a current ratio of 4.06 and a quick ratio of 3.22.

Zynex (NASDAQ:ZYXI) last released its quarterly earnings data on Thursday, July 25th. The company reported $0.04 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.08 by ($0.04). The firm had revenue of $49.88 million for the quarter, compared to analysts’ expectations of $51.99 million. Zynex had a return on equity of 14.15% and a net margin of 3.12%. Zynex’s revenue for the quarter was up 11.0% on a year-over-year basis. During the same period last year, the firm posted $0.09 earnings per share. As a group, analysts forecast that Zynex will post 0.2 earnings per share for the current fiscal year.

Insider Transactions at Zynex

In other news, COO Anna Lucsok sold 8,083 shares of Zynex stock in a transaction on Wednesday, August 7th. The shares were sold at an average price of $8.03, for a total transaction of $64,906.49. Following the completion of the sale, the chief operating officer now directly owns 16,980 shares of the company’s stock, valued at approximately $136,349.40. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, COO Anna Lucsok sold 8,083 shares of the business’s stock in a transaction on Wednesday, August 7th. The shares were sold at an average price of $8.03, for a total value of $64,906.49. Following the completion of the sale, the chief operating officer now directly owns 16,980 shares of the company’s stock, valued at $136,349.40. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Joshua R. Disbrow purchased 7,000 shares of Zynex stock in a transaction that occurred on Monday, July 29th. The stock was bought at an average cost of $8.32 per share, with a total value of $58,240.00. Following the completion of the transaction, the director now owns 72,000 shares of the company’s stock, valued at $599,040. The trade was a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Corporate insiders own 52.13% of the company’s stock.

About Zynex

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.